SF3B2

Splicing factor 3B subunit 2 · Q13435 · SF3B2 on Sugi Atlas →

0 patent compounds predicted against SF3B2, 0 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours

Clinical trials — most relevant to SF3B2 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Valproate and Levocarnitine in Children With Spinal Muscular Atrophy PHASE3UNKNOWN
Anastrozole or Fulvestrant in Treating Postmenopausal Patients With Breast Cancer PHASE2COMPLETED
Enzalutamide and Cabazitaxel in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer PHASE1/PHASE2ACTIVE_NOT_RECRUITING
New Treatment Strategies and Epigenetic Biomarker for Management of Benign Prostatic Hyperplasia PHASE2RECRUITING
Venetoclax Added to Fludarabine + Busulfan Prior to Transplant and to Maintenance Therapy for AML, MDS, and MDS/MPN PHASE1ACTIVE_NOT_RECRUITING
Role of SF3B1 Mutation in Assessment of Acute and Chronic Lymphatic Leukemia nanNOT_YET_RECRUITING
Biocollection in MyeloDysplastic Syndrome (P-MDS) nanRECRUITING
Molecular Disease Profile of Hematological Malignancies nanUNKNOWN
Personalized Medicine Program on Myelodysplastic Syndromes: Characterization of the Patient's Genome for Clinical Decision Making and Systematic Collection of Real World Data to Improve Quality of Health Care nanCOMPLETED
Monitoring Mutational Burden in Low Risk MDS Patients Using Sequential Peripheral Blood Samples nanRECRUITING
GENOMED4ALL: Improving MDS Classification and Prognosis by AI nanUNKNOWN
SRSF2 Gene Mutation in Patients With t-MDS/AML nanCOMPLETED
Becker Muscular Dystrophy - A Natural History Study to Predict Efficacy of Exon Skipping nanUNKNOWN
Efficacy and Safety Study of EGCG/Tocotrienol in 18 Patients With Splicing-mutation-mediated Cystic Fibrosis (CF) nanCOMPLETED
Transcriptomes Breast, Ovarian and Leukocyte Hereditary Genes Predisposing to Breast and / or Ovarian Cancer nanCOMPLETED
Aberrant Splicings Due to Microsatellite Instability in Colorectal Cancer : Physiopathological and Clinical Impact nanUNKNOWN
Prognostic Molecular Markers in Patients With Myelodysplastic Syndrome nanCOMPLETED
Ferroptosis Study in SF3B1-mutant Myelodysplastic Syndromes (FerMDS) nanRECRUITING
Association of SNPs in Long Intergenic Noncoding RNA 00511 (LINC00511) With Breast Cancer Among the Egyptian Population nanCOMPLETED
Patient's Derived Organoids for Drug Screening in Glioblastoma nanNOT_YET_RECRUITING
Prospective Study of Molecular Predictors of Survival in Myelodysplastic Syndromes nanCOMPLETED
Genomic Services Research Program nanRECRUITING
MiRNA223 and HMGB1 as Apredictos for Drug Resistant Epilepsy nanUNKNOWN
Outcome Measures and Biomarkers in a Cohort of Spinal Muscular Atrophy Type III/ IV Patients nanACTIVE_NOT_RECRUITING
SMN Circular RNAs as Potential Biomarkers for the Therapeutic Response to Nusinersen in Spinal Muscular Atrophy Patients nanUNKNOWN
Prevalence of a Non-Expressing 11B Mutation in Aka Peoples of the Central African Republic nanCOMPLETED
Identification and Characterization of Novel Non-Coding Variants That Contribute to Genetic Disorders nanCOMPLETED
Mesenchymal Stem Cells in NPM1 Mutated Low Risk Acute Myeloid Leukemia: a Study of the Tumor Microenvironment and Its Contribution to the Outcome nanCOMPLETED
Study of Individuals and Families With Aberrations in DDX41 or Similar Cancer Predisposition Variants nanRECRUITING
Pharmacogenomic Association Study in Indian Children With Acute Lymphoblastic Leukemia nanRECRUITING

Related proteins — ESM-2 sequence neighbours (a SF3B2 binder may also engage these)

ProteinNameSimilarity
Q3UJB0 1.000 Q3UJB0 →
Q9Y2W2 0.985 Q9Y2W2 →
Q923D5 0.983 Q923D5 →
Q8N2M8 0.983 Q8N2M8 →
P92948 0.983 P92948 →
A0JNI5 0.983 A0JNI5 →
Q9UPY6 0.982 Q9UPY6 →
Q5PQQ2 0.982 Q5PQQ2 →
O08837 0.982 O08837 →
Q8CFC7 0.981 Q8CFC7 →
SRRT Serrate RNA effector molecule homolog 0.981 landscape →
Q2KJC1 0.981 Q2KJC1 →
Q5HZB6 0.980 Q5HZB6 →
SF3A1 Splicing factor 3A subunit 1 0.980 landscape →
Q99MR6 0.980 Q99MR6 →
Q8VHI6 0.979 Q8VHI6 →
Q6A068 0.979 Q6A068 →
A2VDN6 0.979 A2VDN6 →
Q5R539 0.979 Q5R539 →
Q6P0D5 0.978 Q6P0D5 →
Q80UV9 0.978 Q80UV9 →
CDC5L Cell division cycle 5-like protein 0.978 landscape →
Q6PII3 0.978 Q6PII3 →
B1H1X4 0.978 B1H1X4 →
P19351 0.978 P19351 →
Q4VGL6 0.977 Q4VGL6 →
D3ZTQ1 0.977 D3ZTQ1 →
A2VDK6 0.977 A2VDK6 →
Q3UQU0 0.977 Q3UQU0 →
Q8K4Z5 0.977 Q8K4Z5 →